- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Lynparza Phase III PAOLA-1 trial met primary endpo
AnnouncementREG - AstraZeneca PLC - Amendment: Tagrisso significantly improves overall
AnnouncementREG - AstraZeneca PLC - Tagrisso significantly improves overall survival
AnnouncementREG - AstraZeneca PLC - Lynparza Phase III PROfound trial in HRR*
AnnouncementREG - AstraZeneca PLC - Forxiga label updated in the EU in type-2 diabetes
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AZN: H1 2019 Results
AnnouncementREG - AstraZeneca PLC - Update on US regulatory decision for Farxiga
AnnouncementREG - AstraZeneca PLC - Imfinzi granted US Orphan Drug Designation for
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Fasenra receives positive EU CHMP opinion for self
AnnouncementREG - AstraZeneca PLC - Forxiga receives positive EU CHMP opinion for
AnnouncementREG - AstraZeneca PLC - Imfinzi improves overall survival at interim
AnnouncementREG - AstraZeneca PLC - Bevespi Aerosphere approved by the Japanese
AnnouncementREG - AstraZeneca PLC - Lynparza approved in Japan for 1st-line
AnnouncementREG - AstraZeneca PLC - Breztri Aerosphere (PT010) approved in Japan for
AnnouncementREG - AstraZeneca PLC - Lynparza approved in the EU for 1st-line
AnnouncementREG - AstraZeneca PLC - Calquence significantly prolonged the time patient
AnnouncementREG - AstraZeneca PLC - Publication of a Prospectus
Announcement